Esperion Therapeutics, Inc.: operating_income
| Value | {"amount": 54402000, "concept": "us-gaap:OperatingIncomeLoss", "currency": "USD"} |
|---|---|
| Period | 2024-01-01 – 2024-12-31 |
| Status | current |
| Entity | Esperion Therapeutics, Inc. |
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
Retrieved: 2026-08-19T14:06:45.971287+02:00
Raw response sha256:
Also addressable by official identifiers:
Cite as: FACTANKER, https://factanker.com/fact/85b6e7d4-11c9-4144-98f0-c1759a7c519f
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
0001628280-25-011154Retrieved: 2026-08-19T14:06:45.971287+02:00
Raw response sha256:
f7bde1a401b286c74a2fd824ee1df541…Also addressable by official identifiers:
https://factanker.com/fact/sec/cik-0001434868/operating-income/2024-12-31 (CIK, metric, reporting date)Cite as: FACTANKER, https://factanker.com/fact/85b6e7d4-11c9-4144-98f0-c1759a7c519f
History
- no predecessors — first report